Immedica to acquire biopharmaceutical company Marinus Pharmaceuticals

Grafa2024-12-30

Immedica Pharma, a global rare disease company, has announced a definitive agreement to acquire Marinus Pharmaceuticals (NASDAQ:MRNS), a company focused on seizure disorders.

The acquisition, valued at $0.55 per share in cash, represents a 48% premium over Marinus’ closing share price on December 27th and a 97% premium over the 30-day volume-weighted average price.

The deal will bring ZTALMY® (ganaxalone) oral suspension, a treatment for seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two years and older, into Immedica’s portfolio.

ZTALMY® received FDA approval in March 2022.

While Immedica will initiate a tender offer for all outstanding shares of Marinus common stock, the Marinus board of directors has unanimously approved the transaction and recommends that stockholders tender their shares.

This acquisition concludes Marinus’ previously announced review of strategic alternatives, initiated on October 24, 2024, aimed at maximizing stockholder value.

The transaction is expected to close in the first quarter of 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2495493755?lang=en_US&edition=full_marsco","thumbnail":"https://images.grafa.com/grafa/media-health-immedica-to-acquire-biopharmaceutical-company-marinus-pharmaceuticals-340677-638711589151319559.jpeg","is_english":true,"pubTime":"2024-12-30 20:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2495493755","market":null,"top_or_hot":-1,"title":"Immedica to acquire biopharmaceutical company Marinus Pharmaceuticals","media":"Grafa","content":"<img alt=\"\" src=\"https://images.grafa.com/grafa/media-health-immedica-to-acquire-biopharmaceutical-company-marinus-pharmaceuticals-340677-638711589151319559.jpeg\"/><p>Immedica Pharma, a global rare disease company, has announced a definitive agreement to acquire <a href=\"https://laohu8.com/S/MRNS\">Marinus Pharmaceuticals</a> <a href=\"https://grafa.com/asset/marinus-pharmaceuticals-inc-14242-mrns.nasdaq\">(NASDAQ:MRNS)</a>, a company focused on seizure disorders.</p>\n<p>The acquisition, valued at $0.55 per share in cash, represents a 48% premium over Marinus’ closing share price on December 27th and a 97% premium over the 30-day volume-weighted average price.  </p>\n<p>The deal will bring ZTALMY® (ganaxalone) oral suspension, a treatment for seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two years and older, into Immedica’s portfolio.</p>\n<p>ZTALMY® received FDA approval in March 2022.  </p>\n<p>While Immedica will initiate a tender offer for all outstanding shares of Marinus common stock, the Marinus board of directors has unanimously approved the transaction and recommends that stockholders tender their shares. </p>\n<p>This acquisition concludes Marinus’ previously announced review of strategic alternatives, initiated on October 24, 2024, aimed at maximizing stockholder value.  </p>\n<p>The transaction is expected to close in the first quarter of 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immedica to acquire biopharmaceutical company Marinus Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmedica to acquire biopharmaceutical company Marinus Pharmaceuticals\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1019687050\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/b5820fc70e21f7eb65d05d7a2a3e6c15);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Grafa </p>\n<p class=\"h-time\">2024-12-30 20:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<img alt=\"\" src=\"https://images.grafa.com/grafa/media-health-immedica-to-acquire-biopharmaceutical-company-marinus-pharmaceuticals-340677-638711589151319559.jpeg\"/><p>Immedica Pharma, a global rare disease company, has announced a definitive agreement to acquire <a href=\"https://laohu8.com/S/MRNS\">Marinus Pharmaceuticals</a> <a href=\"https://grafa.com/asset/marinus-pharmaceuticals-inc-14242-mrns.nasdaq\">(NASDAQ:MRNS)</a>, a company focused on seizure disorders.</p>\n<p>The acquisition, valued at $0.55 per share in cash, represents a 48% premium over Marinus’ closing share price on December 27th and a 97% premium over the 30-day volume-weighted average price.  </p>\n<p>The deal will bring ZTALMY® (ganaxalone) oral suspension, a treatment for seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two years and older, into Immedica’s portfolio.</p>\n<p>ZTALMY® received FDA approval in March 2022.  </p>\n<p>While Immedica will initiate a tender offer for all outstanding shares of Marinus common stock, the Marinus board of directors has unanimously approved the transaction and recommends that stockholders tender their shares. </p>\n<p>This acquisition concludes Marinus’ previously announced review of strategic alternatives, initiated on October 24, 2024, aimed at maximizing stockholder value.  </p>\n<p>The transaction is expected to close in the first quarter of 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDD.AU","symbol_name":"CARDNO LTD","start_time":0,"source_url":"https://grafa.com/news/health-immedica-to-acquire-biopharmaceutical-company-marinus-pharmaceuticals-340677?referralcode=A314DFDBE96C354756A893C6E3E02493","article_id":"2495493755","we_media_id":"1019687050","thumbnails":["https://images.grafa.com/grafa/media-health-immedica-to-acquire-biopharmaceutical-company-marinus-pharmaceuticals-340677-638711589151319559.jpeg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2495493755","pubTimestamp":1735562073,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Grafa","introduction":"Grafa generates AI-driven data, news and analysis about NYSE, Nasdaq and ASX stocks as well as forex, crypto and economic news. News is generated in near real-time due to Grafa's unique data-led approach to media content generation.","home_visible":1,"id":"1019687050","head_image":"https://static.tigerbbs.com/b5820fc70e21f7eb65d05d7a2a3e6c15"},"summary":"Immedica Pharma, a global rare disease company, has announced a definitive agreement to acquire Marinus Pharmaceuticals , a company focused on seizure disorders.The acquisition, valued at $0.55 per share in cash, represents a 48% premium over Marinus’ closing share price on December 27th and a 97% premium over the 30-day volume-weighted average price.The deal will bring ZTALMY  oral suspension, a treatment for seizures associated with cyclin-dependent kinase-like 5  deficiency disorder  in patients two years and older, into Immedica’s portfolio.While Immedica will initiate a tender offer for all outstanding shares of Marinus common stock, the Marinus board of directors has unanimously approved the transaction and recommends that stockholders tender their shares.This acquisition concludes Marinus’ previously announced review of strategic alternatives, initiated on October 24, 2024, aimed at maximizing stockholder value.The transaction is expected to close in the first quarter of 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CDD.AU":"CARDNO LTD","BK7047":"环境与设施服务"},"translate_title":"Immedica将收购生物制药公司Marinus Pharmaceuticals","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDD.AU":1},"content_text":"Immedica Pharma, a global rare disease company, has announced a definitive agreement to acquire Marinus Pharmaceuticals (NASDAQ:MRNS), a company focused on seizure disorders.\nThe acquisition, valued at $0.55 per share in cash, represents a 48% premium over Marinus’ closing share price on December 27th and a 97% premium over the 30-day volume-weighted average price.  \nThe deal will bring ZTALMY® (ganaxalone) oral suspension, a treatment for seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two years and older, into Immedica’s portfolio.\nZTALMY® received FDA approval in March 2022.  \nWhile Immedica will initiate a tender offer for all outstanding shares of Marinus common stock, the Marinus board of directors has unanimously approved the transaction and recommends that stockholders tender their shares. \nThis acquisition concludes Marinus’ previously announced review of strategic alternatives, initiated on October 24, 2024, aimed at maximizing stockholder value.  \nThe transaction is expected to close in the first quarter of 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2495493755"}